Indero Celebrates Successful Launch of Its 40th RTSM Study on Veeva Platform

Indero Marks a Significant Milestone in Clinical Trials

In a notable advancement in the field of clinical research, Indero, previously known as Innovaderm Research, has launched its 40th Randomization and Trial Supply Management (RTSM) study using Veeva RTSM, a cutting-edge cloud software designed for the life sciences industry. This achievement not only highlights Indero's commitment to innovation but also reflects its strategic alignment with Veeva Systems.

Since its inception, Indero has been dedicated to streamlining clinical trial processes, and integrating Veeva RTSM has played a critical role in this endeavor. The collaboration aims to enhance the efficiency, consistency, and execution of clinical studies, ensuring timely delivery of effective therapies to patients. Eric Hardy, the Senior Director of Biometrics at Indero, emphasized the company's dedication to optimizing trial operations. "As we continue to streamline our clinical trial processes, Veeva RTSM allows us to foster greater collaboration and improved efficiency in execution. This capability enables us to bring therapies to market more swiftly, benefiting sponsors, sites, and patients alike."

The implementation of Veeva RTSM has streamlined the procedural aspects of Indero's clinical trials while maintaining a high standard of quality and reliability. By standardizing operations through Veeva's robust platform, Indero has noted significant improvements in its study timelines. Steve Simmerman, General Manager of Veeva RTSM, commented on the partnership, stating, "Indero's approach to adopting enterprise-standard RTSM has yielded long-term benefits, increasing reliability and efficiency in their studies. This collaboration not only accelerates study timelines but also sets a benchmark for the industry as a whole."

Indero's journey with Veeva RTSM began when it sought to enhance its clinical trial methodologies and upgrade its technology stack. The decision to partner with Veeva represents a significant shift toward a more standardized and efficient clinical research framework. This strategic move enables Indero to better meet the evolving needs of its clients, including pharmaceutical companies and emerging biotechs, by streamlining complex processes involved in clinical trials, ultimately reducing costs and expediting timelines.

Moreover, as Indero reaches this milestone, it serves as a reminder of how collaborative efforts and advancements in technology are essential to propelling the life sciences industry forward. The union of Indero's clinical expertise and Veeva's innovative solutions creates a solid foundation for future studies, paving the way for enhanced patient outcomes and quicker access to essential therapies.

As the demand for swift and effective drug development grows, companies like Indero are crucial for driving innovation in the clinical research sphere. Their 40th RTSM study launch marks not just an accomplishment for the organization but represents a collective effort in the fight against diseases through better clinical research practices.

In conclusion, Indero's successful launch of its 40th RTSM study is a testament to the power of technology in clinical trials. This remarkable achievement reinforces the importance of cooperation between research organizations and technology providers in improving the process of bringing novel therapies to market.

For more information on Veeva's enterprise-standard RTSM, visit their official website at www.veeva.com/rtsm.